[Pyr1]-Apelin-13 (Human, Bovine)
4361-v 0.5 mg | 70.00 EUR
The purity is guaranteed to be higher than 99% by HPLC
Ligand for APJ Receptor
Apelin has been described as endogenous ligand for human APJ. Its pyroglutaminated C-terminal peptide [Pyr1]-Apelin-13 ( [pGlu]-Apelin-13 ) was more potent than Apelin-36 in competitive inhibition assays. This pyroglutaminated peptide shows in vivo very high vascular effects. [Pyr1]-Apelin-13 shows a clear vasodilation effect in man.
- K. Tatemoto, M. Hosoya, Y. Habata, R. Fujii, T. Takegawa, M.-X. Zou, Y. Kawamata, S. Fukusumi, S. Hinuma, C. Kitada, T. Kurokawa, H. Onda and M. Fujino, Biochem. Biophys. Res. Commun., 251, 471 (1998) (Original; Human and Bovine)
- M.X. Zou, H.Y. Liu, Y. Haraguchi, Y. Soda, K. Tatemoto and H. Hoshido, FEBS Lett., 473, 15 (2000) (Pharmacol.)
- M. Hosoya, Y. Kawamata, S. Fukusumi, R. Fujii, Y. Habata, S. Hinuma, C. Kitada, S. Honda, T. Kurukawa, H. Onda, O. Nishimura and M. Fujino, J. Biol. Chem., 275, 21061 (2000) (Pharmacol.)
The synthetic peptide [Pyr1]-Apelin-13 is distributed through Peptide Institute, Inc. under the license of Takeda Pharmaceutical Company , Ltd.